Annovis Bio Inc expected to post a loss of 36 cents a share - Earnings Preview
06/05/2025 23:20
Annovis Bio Inc ANVS.N, ANVS.K is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2025 ​LSEG's mean analyst estimate for Annovis Bio Inc is for a loss of 36 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts had fallen by about 8.6% in the last three months. ​ Wall Street's median 12-month price target for Annovis Bio Inc is $25.00​, above​ its last closing price of $1.44. ​​​ Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.29 | -0.33 | -0.43 | Missed | -30.1 |
| Sep. 30 2024 | -0.54 | -0.53 | -0.97 | Missed | -84.4 |
| Jun. 30 2024 | -0.69 | -0.63 | -0.32 | Beat | 49.2​ |
| Mar. 31 2024 | -0.84 | -0.80 | -0.10 | Beat | 87.5 |
| ​​Dec. 31 2023 | -1.39 | -1.30 | -2.24 | Missed | -71.7 |
| Sep. 30 2023 | -1.06 | -1.09 | -1.63 | Missed | -49.5​ |
| Jun. 30 2023 | -1.11 | -1.14 | -1.07 | Beat | 6.3 |
| Mar. 31 2023 | -0.33 | -0.33 | -1.19 | Missed | -256.3 |
Recent news on Annovis Bio
See all newsAnnovis Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Annovis Bio Q2 loss widens as R&D costs rise
Annovis Bio Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Annovis Announces Pricing Of $15.0 Million Public Offering Of Common Stock And Accompanying Warrants
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman